Lol Ridge!
I was buying the dips then too. In fairness to our down ramping friends it was true that success was years away and uncertain, but as I replied to them at the time - that's exactly why Imugene was so cheap. The old risk vs reward ratio. Their antics did cause me to go back and research even more deeply into the science but, after doing that, on calm reflection I felt that the risks - even then - were less than most people thought. So I added to my holding every time it dipped.
I have always been ready to bail out if the science (and/or the management) gave me genuine cause for concern - but I have never seen any sign that the Her-Vaxx science was faulty, and so far the same is true for the portfolio of B-cell therapies which came in through Prof Kaumaya, and then CF33 with Prof Fong. In fact each Announcement has strengthened the case with regard to all three areas of IP. Likewise, the management team has become stronger and stronger each year. I wish my only other major Biotech investment had such a strong team behind it.
So - lucky us to be multi-bags from 0.08c, but Imugene has made amazing progress since those days and I feel that today's close of 18c is more than justified. When you consider that we have good reason to expect further good news from the final Her-Vaxx Ph 2 results - quite possibly even better than the excellent interim data - a deal for further development and commercialisation of Her-Vaxx now looks like a real possibility. Such a deal could multi-bag Imugene again, even from today's closing price.
And then the incredibly exciting interim results for the PD1-vaxx.....
Plus CF33 in both forms - highly likely to get IND very soon and potentially a company maker on it's own.
With the little mentioned B-vaxx Phase 2 trial still in progress, but scheduled to end in December. I have been reading back through what we know about B-vaxx. That trial has been going a very long while - which could actually be a good sign. I will try and post my thoughts about B-vaxx over the weekend.
Many junior biotechs have just a single hopeful drug candidate. Imugene has at least three with blockbuster potential, and if that's not enough for you, Her-Vaxx was developed through a Mimotope platform technology which can potentially be used to produce a B cell therapy which mimics the effect of any successful MAB on the market. Indeed, the Medical University of Vienna team have already used it to produce a PD1 vaccine themselves, and Imugene looked likely to progress that drug until they did the deal with Prof Kaumaya in mid 2018 for his entire B cell portfolio. Prof Kaumaya's PD1 vaccine was 18 months further down the development path, so they went with that one instead of the Vienna version.
The early data from PD1-vaxx shows that they made a good call, but you can read about the Vienna PD1 vaccine announcement from Feb 2018 and wonder what that might also achieve:
https://hotcopper.com.au/threads/ann-novel-anti-pd-1-mimotope-vaccine-ready-for-development.4012477/Since 20/1/16 Imugene has had a licence to use the Vienna team's Mimotope platform to produce other B cell vaccines, and they own the IP of any vaccine they produce.
https://hotcopper.com.au/threads/ann-partnership-to-develop-mimotope-immuno-oncology-platform.2682798/In fact, including the "Vienna PD1" but not including Her-vaxx or any of Prof Kaumaya's vaccines -
Imugene already holds patents for 3 other B cell vaccine formulations - each of them targeting the same mechanism of action as a major current market blockbuster drug. A quote from their Ann of 19/12/16: "Each of the targets already has a monoclonal antibody synthetic drug on market generating sales in the hundreds of millions treating cancers such as melanoma, non-small cell lung cancer, multiple myeloma and bladder cancer." A 4th patent protects the Mimotope technology itself - with all patents good to 2037. Source:
https://hotcopper.com.au/threads/ann-imugene-progresses-mimotope-platform.3121994/Newer investors will have been attracted to Imugene - quite rightly - by issues such as:
- the excellent interim Phase 2 results for Her-Vaxx
- the incredibly exciting results so far from PD1-vaxx Phase 1
- the absolutely tantalising in vitro and animal model results for CF33.
- the fulfilling sense that this is a truly ethical investment, helping people win their way back to health and life
Each of those is a good reason too buy Imugene at current SP levels or above.
For me, it is a combination of all of that, but also the astonishing depth of the IP they have built up and what that says about the quality of both the Imugene Board and the Scientific Advisory Board, plus the three main research teams Imugene is working in partnership with (Vienna/Prof Widermann and team; City of Hope/Prof Fong and team; University of Ohio/Prof Kaumaya and team. Oh - and Imugene's own team, who are competently steering multiple clinical trials across several continents. Amazing!
And I haven't even mentioned the Arginine modulators .....
Anyway - it's not investment advice - just a summary of facts as I understand them, plus a little dash of my own opinion thrown in - but I hope this will be of interest to newer shareholders and a potential boost to your confidence. Welcome aboard! The good ship Imugene is perhaps a little larger than you realised. The weather looks to be set fair. The Captain and crew are first rate. We sail with the tide.
Let's see where the voyage takes us!
Cheers and happy weekend wishes for every voyage you may take.
Dave
